U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07363382) titled 'The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer' on Jan. 16.
Brief Summary: The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer, particularly serving as a complementary tool to PSMA PET for addressing cases with negative or insufficient PSMA expression. It demonstrates substantial value in initial staging (especially in intermediate- and high-risk patients), detecting sites of biochemical recurrence, assessing metastatic lesions (notab...